An Observational Study of the First Experience with Bevacizumab
for the Treatment of Patients with Recurrent High-Grade Glioma in
Two Belgian University Hospitals
Figure 4
Case illustration of a tumor response on BEV therapy. Baseline images by gadolinium-enhanced T1 MRI, T2, and 11C-Methionine-PET on the left hand (top to bottom) and images obtained after 2 administrations of BEV. The patient remained free from progression after more than 1 year of BEV therapy.
